Collagen and Its Roles in the Tumor Immune Microenvironment: Structure, Function, and Therapeutic Potential
Open Access
- 22 December 2025
- journal article
- review article
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (12) , 45052
Abstract
Collagen, the primary structural protein of the extracellular matrix, shows marked structure–function duality in the tumor immune microenvironment (TIME). Biomechanical and biophysical alterations—matrix stiffening, viscoelastic energy dissipation, fiber alignment and tumor-associated collagen signatures, reduced pore size, and solid stress—create migration tracks, sequester signaling cues that regulate proliferation and metabolism, and from dense barriers that impede immune infiltration. These changes are sensed and transduced via mechanosensing and mechanotransduction pathways, thereby reinforcing malignant behavior and immune exclusion. Given its dynamic, spatiotemporally regulated roles, collagen is a promising therapeutic target to overcome immunotherapy resistance. This review examines the structural features, biological functions, and regulatory pathways of collagen within the TIME. Based on these insights, several clinical strategies were highlighted: targeting cancerassociated fibroblasts and profibrotic signaling to reduce fibrosis; remodeling the matrix enzymatically or physically; and inhibiting collagen receptor signaling. These approaches are often combined with immune checkpoint inhibition. Future directions will emphasize biomarker-guided stratification of collagen status; combining therapies informed by mechanobiology; and using scalable, noninvasive monitoring to optimize immunotherapy outcomes.Keywords
This publication has 83 references indexed in Scilit:
- Multifunctional nanoparticles and collagenase dual loaded thermosensitive hydrogel system for enhanced tumor-penetration, reversed immune suppression and photodynamic-immunotherapyBioactive Materials, 2025
- Intratumoral Collagen Deposition Supports Angiogenesis Suggesting Anti‐angiogenic Therapy in Armored and Cold TumorsAdvanced Science, 2025
- Targeting Fibrosis: From Molecular Mechanisms to Advanced TherapiesAdvanced Science, 2024
- Conserved immuno‐collagenic subtypes predict response to immune checkpoint blockadeCancer Communications, 2024
- Substrate stiffness modulates bone marrow-derived macrophage polarization through NF-κB signaling pathwayBioactive Materials, 2020
- Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2015
- Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasPediatric Blood & Cancer, 2014
- Aligned Collagen Is a Prognostic Signature for Survival in Human Breast CarcinomaThe American Journal of Pathology, 2011
- Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancerBreast Cancer Research and Treatment, 2010
- Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanomaCancer, 2006